Tsuburaya 2012.

Trial name or title	A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S‐1 plus cisplatin (SP) as a first‐line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II)
Methods	Multicentre RCT 2 arms
Participants	N = 100 (planned)
Interventions	Arm A: S‐1 (40 mg/m² twice a day d1‐21) + cisplatin (60 mg/m² d 8) repeated at d 35 versus Arm B: capecitabine (1000 mg/² d1‐14) + cisplatin (80 mg/m² d 1) repeated at d 21
Outcomes	Progression‐free survival, overall survival, time to treatment failure, tumour response, safety
Starting date	August 2011
Contact information	Akira Tsuburaya, Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 1‐1‐2, Nakao, 241‐0815, Yokohama, Asahi‐ku, Japan, tuburayaa@kcch.jp
Notes	The study is registered (NCT01406249), the study protocol is published. Estimated study completion date is June 2015. The study is not yet published.

5‐FU: 5‐fluorouracil
 ci: continuous infusion
 d: day
 E: epirubicin
 G‐CSF: granulocyte colony stimulating factor
 PFS: progression‐free survival
 RCT: randomised controlled trial